We aim to evaluate the efficacy of selective aldosterone receptor antagonism with eplerenone added to optimal medical treatment in improving cardiac structure and function in diabetic cardiomyopathy. The gene discussed is NR3C2; the disease is diabetic cardiomyopathy.